Gracell Biotechnologies Inc.

For Q3 2023, Gracell reported cash and cash equivalents plus short-term investments of RMB1,707.9 million, or US$234.1 million, as of September 30, 2023. Net loss attributable to ordinary shareholders was RMB67.6 million, or US$9.3 million, versus RMB171.9 million in the prior-year quarter; R&D expense was RMB90.1 million, or US$12.3 million, versus RMB133.4 million a year earlier. Management said the lower loss was mainly due to a RMB39.9 million, or US$5.5 million, decrease in the fair value of warrant liabilities. Looking ahead, the company expects 2023 cash use of about US$100 million and said its cash is sufficient into the second half of 2026 if the warrants are fully exercised. In the pipeline, Gracell expects to begin RRMM enrollment in China this quarter, continue U.S. site activations, and expects first public SLE IIT readout in the first half of 2024 with double-digit patients and at least three months of follow-up for most, some with six months.

William Cao framed the quarter as a period of major pipeline momentum, highlighting the first U.S. patient dosing in RRMM, updated IMS data for GC012F, progression of the SLE program, and preclinical solid-tumor work. He repeatedly stressed that GC012F’s combination of rapid manufacturing, strong safety, and dual CD19/BCMA biology could make it differentiated in oncology and autoimmune disease. His tone was confident but cautious on timing, especially around when more mature SLE and early-line myeloma data can support regulatory discussions.

Kevin Xie focused on liquidity and the quarter’s financial profile. He said Gracell ended Q3 with RMB1,707.9 million, or US$234.1 million, in cash and short-term investments, expects full-year cash use of about US$100 million, and believes the August financing extends runway into the second half of 2026 if warrants are fully exercised. On the P&L, he pointed to a Q3 net loss of RMB67.6 million, or US$9.3 million, and R&D expense of RMB90.1 million, or US$12.3 million, both below the prior-year quarter, with the net loss improvement largely driven by a lower fair value of warrant liabilities.

Analysts focused on how much the dual CD19/BCMA construct matters biologically, especially the share of CD19-negative antibody-secreting cells, and management said exact percentages vary and are still being collected, but the cells are clearly BCMA-positive and dual targeting appears to be more than additive in ex vivo assays, with more than 10-fold greater inhibition versus CD19-only CAR-T. Questions also centered on SLE timing, dose levels, and durability; management said first-half 2024 should bring double-digit patient data with at least three months of follow-up for most, and that dosing is being escalated up to 3x10^5 cells/kg but likely not above that. Analysts asked about the U.S. regulatory path for early-line NDMM and partner interest, and management said it is too early to define a pivotal design, but that the 1b RRMM data and an end-of-phase-1 discussion with the FDA should inform next steps, while partner conversations are ongoing in both oncology and immunology.